These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 24283844)

  • 21. A comparison of immunotherapy delivery methods for allergen immunotherapy.
    Klimek L; Pfaar O
    Expert Rev Clin Immunol; 2013 May; 9(5):465-74; quiz 475. PubMed ID: 23634740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Is faster safer? Cluster versus short conventional subcutaneous allergen immunotherapy.
    Quiralte J; Justicia JL; Cardona V; Dávila I; Moreno E; Ruiz B; García MA
    Immunotherapy; 2013 Dec; 5(12):1295-303. PubMed ID: 24283840
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunological mechanisms of allergen-specific immunotherapy.
    Larché M; Akdis CA; Valenta R
    Nat Rev Immunol; 2006 Oct; 6(10):761-71. PubMed ID: 16998509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The optimal immunotherapy cluster schedule in clinical practice.
    Fernández-Távora L; Moreno C; Martín S; Rico P
    J Investig Allergol Clin Immunol; 2003; 13(3):193-201. PubMed ID: 14635470
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [The progress on allergen-specific immunotherapy for bronchial asthma].
    Liu HY; Xie LY; Zhou LF
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Jun; 36(6):450-4. PubMed ID: 24103210
    [No Abstract]   [Full Text] [Related]  

  • 26. Advances in patent applications related to allergen immunotherapy.
    Silva ES; Pinheiro CS; Quintella CM; Ferreira F; C Pacheco LG; Alcântara-Neves NM
    Expert Opin Ther Pat; 2016 Jun; 26(6):657-68. PubMed ID: 27011299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Very late reactions to allergen-specific immunotherapy caused by physical exercise.
    Rotne H
    Allergy; 2000 Feb; 55(2):194. PubMed ID: 10726737
    [No Abstract]   [Full Text] [Related]  

  • 28. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunologic responses to subcutaneous allergen immunotherapy.
    Till SJ; Durham SR
    Clin Allergy Immunol; 2008; 21():59-70. PubMed ID: 18828498
    [No Abstract]   [Full Text] [Related]  

  • 30. Safety aspects of subcutaneous immunotherapy with multiple allergens--a retrospective analysis on polysensitized patients.
    Barth C; Anero F; Pfaar O; Klimek L; Hörmann K; Stuck BA
    Eur Arch Otorhinolaryngol; 2010 Dec; 267(12):1873-9. PubMed ID: 20454971
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Shooting for a faster approach to the immunotherapy target: will cluster become conventional?
    Cox LS
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):177-8. PubMed ID: 19354062
    [No Abstract]   [Full Text] [Related]  

  • 32. IgE-mediated allergen presentation and blocking antibodies: regulation of T-cell activation in allergy.
    van Neerven RJ; Knol EF; Ejrnaes A; Würtzen PA
    Int Arch Allergy Immunol; 2006; 141(2):119-29. PubMed ID: 16864979
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developments in allergen-specific immunotherapy: from allergen extracts to allergy vaccines bypassing allergen-specific immunoglobulin E and T cell reactivity.
    Focke M; Swoboda I; Marth K; Valenta R
    Clin Exp Allergy; 2010 Mar; 40(3):385-97. PubMed ID: 20210812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Incidence and risk factors for subcutaneous immunotherapy anaphylaxis: the optimization of safety.
    Caminati M; Dama AR; Djuric I; Montagni M; Schiappoli M; Ridolo E; Senna G; Canonica GW
    Expert Rev Clin Immunol; 2015 Feb; 11(2):233-45. PubMed ID: 25484197
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Local reactions during allergen immunotherapy do not require dose adjustment.
    Tankersley MS; Butler KK; Butler WK; Goetz DW
    J Allergy Clin Immunol; 2000 Nov; 106(5):840-3. PubMed ID: 11080704
    [TBL] [Abstract][Full Text] [Related]  

  • 37. European Survey on Adverse Systemic Reactions in Allergen Immunotherapy (EASSI): a real-life clinical assessment.
    Calderón MA; Vidal C; Rodríguez Del Río P; Just J; Pfaar O; Tabar AI; Sánchez-Machín I; Bubel P; Borja J; Eberle P; Reiber R; Bouvier M; Lepelliez A; Klimek L; Demoly P;
    Allergy; 2017 Mar; 72(3):462-472. PubMed ID: 27718250
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Comparison of injection-related and local immunotherapy].
    Kuna P
    Pol Merkur Lekarski; 2003 Jun; 14(84):695-9. PubMed ID: 14524308
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Safety and tolerability of immunotherapy using various updosing schedules of a new SCIT product with an optimised allergen/aluminium hydroxide ratio.
    Jung K
    Allergy; 2011 Jul; 66 Suppl 95():41-3. PubMed ID: 21668852
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dendritic cells in allergen-specific immunotherapy.
    Novak N
    Drugs Today (Barc); 2008 Dec; 44 Suppl B():91-2. PubMed ID: 19221629
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.